Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

X4 Pharmaceuticals (XFOR) EBIT (2018 - 2025)

Historic EBIT for X4 Pharmaceuticals (XFOR) over the last 8 years, with Q3 2025 value amounting to -$27.5 million.

  • X4 Pharmaceuticals' EBIT rose 2026.38% to -$27.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$98.9 million, marking a year-over-year decrease of 28207.07%. This contributed to the annual value of -$36.4 million for FY2024, which is 6614.55% up from last year.
  • Latest data reveals that X4 Pharmaceuticals reported EBIT of -$27.5 million as of Q3 2025, which was up 2026.38% from -$26.2 million recorded in Q2 2025.
  • In the past 5 years, X4 Pharmaceuticals' EBIT registered a high of $71.1 million during Q2 2024, and its lowest value of -$37.3 million during Q1 2024.
  • Its 5-year average for EBIT is -$20.0 million, with a median of -$25.6 million in 2022.
  • Its EBIT has fluctuated over the past 5 years, first skyrocketed by 37553.96% in 2024, then crashed by 13689.3% in 2025.
  • X4 Pharmaceuticals' EBIT (Quarter) stood at -$29.1 million in 2021, then increased by 11.97% to -$25.6 million in 2022, then increased by 1.48% to -$25.2 million in 2023, then crashed by 41.73% to -$35.7 million in 2024, then rose by 22.98% to -$27.5 million in 2025.
  • Its EBIT was -$27.5 million in Q3 2025, compared to -$26.2 million in Q2 2025 and -$9.4 million in Q1 2025.